Search
Prenetics Global Ltd
PREAdd to Watchlist
16.220USD
-1.370-7.79%
Market hours （ET）Quotes delayed by 15 min
209.14MMarket Cap
LossP/E TTM
More Details of Prenetics Global Ltd Company
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.
Prenetics Global Ltd Info
Ticker SymbolPRE
Company namePrenetics Global Ltd
IPO dateJul 06, 2021
CEOKwok (Samantha)
Number of employees285
Security typeOrdinary Share
Fiscal year-endJul 06
AddressUnit 703-706, K11 Atelier King's Road, 728 King's Road, Quarry Bay
City
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryHong Kong
Postal code- -
Phone85222109588
Websitehttps://ir.prenetics.com/
Ticker SymbolPRE
IPO dateJul 06, 2021
CEOKwok (Samantha)
Company Executives of Prenetics Global Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Sheng Wu (Danny) Yeung
Mr. Sheng Wu (Danny) Yeung
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. Yin Pan (Ben) Cheng
Mr. Yin Pan (Ben) Cheng
Independent Director
Independent Director
--
--
Ms. Wing Kwan (Winnie) Chiu
Ms. Wing Kwan (Winnie) Chiu
Independent Director
Independent Director
--
--
Dr. Chi Hung (Lawrence) Tzang, Ph.D.
Dr. Chi Hung (Lawrence) Tzang, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
Mr. Hoi Chun (Stephen) Lo
Mr. Hoi Chun (Stephen) Lo
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Senthil Sundaram, M.D.
Dr. Senthil Sundaram, M.D.
Chief Clinical Officer
Chief Clinical Officer
--
--
Dr. Yung Ho (Peter) Wong
Dr. Yung Ho (Peter) Wong
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Joel Neoh
Mr. Joel Neoh
Chief Consumer Officer, Chief Executive Officer of CircleDNA
Chief Consumer Officer, Chief Executive Officer of CircleDNA
--
--
Ms. Kathryn Henry
Ms. Kathryn Henry
Independent Director
Independent Director
--
--
Mr. David Vanderveen
Mr. David Vanderveen
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Sheng Wu (Danny) Yeung
Mr. Sheng Wu (Danny) Yeung
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. Yin Pan (Ben) Cheng
Mr. Yin Pan (Ben) Cheng
Independent Director
Independent Director
--
--
Ms. Wing Kwan (Winnie) Chiu
Ms. Wing Kwan (Winnie) Chiu
Independent Director
Independent Director
--
--
Dr. Chi Hung (Lawrence) Tzang, Ph.D.
Dr. Chi Hung (Lawrence) Tzang, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
Mr. Hoi Chun (Stephen) Lo
Mr. Hoi Chun (Stephen) Lo
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Senthil Sundaram, M.D.
Dr. Senthil Sundaram, M.D.
Chief Clinical Officer
Chief Clinical Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Hong Kong
14.27M
46.59%
Taiwan
7.09M
23.16%
The United States
5.51M
18.00%
United Kingdom
2.78M
9.08%
Rest of the world
972.00K
3.17%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, May 13
Updated: Wed, May 13
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Dennis (Lo Yuk Ming)
6.19%
Lawrence (Tzang Chi Hung)
3.45%
Genetel Bioventures Ltd
3.14%
Eastspring Investments (Singapore) Limited
2.75%
Aspex Management (HK) Limited
2.22%
Other
82.25%
Shareholders
Shareholders
Proportion
Dennis (Lo Yuk Ming)
6.19%
Lawrence (Tzang Chi Hung)
3.45%
Genetel Bioventures Ltd
3.14%
Eastspring Investments (Singapore) Limited
2.75%
Aspex Management (HK) Limited
2.22%
Other
82.25%
Shareholder Types
Shareholders
Proportion
Individual Investor
10.68%
Hedge Fund
3.90%
Investment Advisor
3.66%
Corporation
3.14%
Research Firm
2.82%
Investment Advisor/Hedge Fund
0.81%
Pension Fund
0.13%
Bank and Trust
0.09%
Other
74.77%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
46
1.76M
11.33%
-778.48K
2025Q4
24
1.19M
9.52%
-1.35M
2025Q3
23
1.16M
9.26%
-1.28M
2025Q2
30
3.73M
32.59%
-1.27M
2025Q1
31
3.72M
35.24%
-295.48K
2024Q4
35
3.71M
34.90%
-336.29K
2024Q3
37
3.69M
34.65%
-448.54K
2024Q2
38
3.76M
35.34%
-535.47K
2024Q1
88
5.56M
55.93%
+1.27M
2023Q4
94
4.17M
42.91%
+30.90K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Dennis (Lo Yuk Ming)
962.96K
7.69%
--
--
Apr 24, 2025
Lawrence (Tzang Chi Hung)
537.10K
4.29%
--
--
Apr 24, 2025
Genetel Bioventures Ltd
613.79K
4.9%
--
--
Sep 30, 2024
Eastspring Investments (Singapore) Limited
427.96K
3.42%
--
--
Dec 31, 2025
Aspex Management (HK) Limited
346.15K
2.76%
--
--
Dec 31, 2025
Nomura Securities Co., Ltd.
268.00K
2.14%
-49.00K
-15.46%
Dec 31, 2025
Chun (Lo Hoi)
162.62K
1.3%
--
--
Apr 24, 2025
683 Capital Management LLC
75.00K
0.6%
+75.00K
--
Dec 31, 2025
Millennium Management LLC
51.43K
0.41%
+51.43K
--
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.03%
iShares Micro-Cap ETF
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Nov 01, 2023
Merger
15→1
Nov 01, 2023
Merger
15→1
Nov 01, 2023
Merger
15→1
Nov 01, 2023
Merger
15→1
Date
Ex-dividend Date
Type
Ratio
Nov 01, 2023
Merger
15→1
Nov 01, 2023
Merger
15→1
Nov 01, 2023
Merger
15→1
Nov 01, 2023
Merger
15→1
